This study is testing if adding nivolumab, a special protein called a monoclonal antibody, to standard cancer treatments paclitaxel and ramucirumab helps people with advanced stomach or esophageal cancer. Nivolumab may help the body's immune system fight cancer. Ramucirumab stops new blood vessels from growing, which tumors need. Paclitaxel helps stop cancer cells from growing. The study will check if adding nivolumab helps people live longer without the cancer getting worse.
- The study lasts up to 3 years with follow-ups every 6 months.
- Participants will receive treatments through a vein (IV) and need regular scans.
- Participants must have specific cancer types and meet health requirements to join.
It's important for participants to have regular check-ups and scans. They must not have certain health issues, like major recent surgeries or untreated infections. This study aims to improve treatment for advanced cancer patients by testing a combination of existing and new therapies.